




## Clinical Evidence for CytoSorb® Therapy in Rhabdomyolysis


Name	Title	Aim	Number of patients	Type of study	Outcome
 <b>Scharf et al., Crit Care 2021; 25(1): 41</b>	Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis.	Patients with severe rhabdomyolysis (various etiologies), median myoglobin for whole gp >25,000 ng/ml, put on renal replacement with CytoSorb® and myoglobin levels measured pre and post adsorber.	43	Case series	Overall myoglobin reduced by 29%, with 38% reduction in patients without ongoing rhabdomyolysis thereby helping to avoid permanent kidney damage.
 <b>Immohr et al., J Card Surg 2020; 35(4): 940 - 1</b>	Successful treatment of a severe case of rhabdomyolysis following heart transplantation by hemoadsorption.	Case of a post orthotopic heart treatment patient who developed cardiogenic shock and arrhythmias requiring veno-arterial extracorporeal membrane oxygenation (va-ECMO) and eventually severe rhabdomyolysis. CytoSorb® was installed into the ECMO circuit.	1	Case report	As soon as CytoSorb® was installed the patient stabilized, his myoglobin levels rapidly and continuously decreased. No problems were noted with plasma concentrations of immunosuppressive drugs. At 6 month follow up patient had full renal function.
 <b>Dilken et al., Blood Purif 2020; 49(6): 743 - 7</b>	Successful reduction of creatine kinase and myoglobin levels in severe rhabdomyolysis using extracorporeal blood purification (CytoSorb®).	Case of severe traumatic crush injury treated with CytoSorb® to reduce myoglobin and creatinine kinase (CK) levels that were unresponsive to high dose continuous renal replacement therapy (CRRT).	1	Case report	Within 4 hours myoglobin and CK levels had reduced from 110,000 to 90,000 mg/l and 115,000 - 65,000 U/L respectively. The adsorber was changed after 12 hours due to evidence of saturation which reduced myoglobin and creatine kinase levels further despite ongoing tissue ischemia.





## Clinical Evidence for CytoSorb® Therapy in Rhabdomyolysis

Name	Title	Aim	Number of patients	Type of study	Outcome
 <b>Wiegele &amp; Krenn, ASAIO J 2015; 61(3): e14 - 6</b>	CytoSorb® in a patient with Legionella-Pneumonia associated rhabdomyolysis: a case report.	Describe the case of severe rhabdomyolysis caused by Legionella pneumophila where CytoSorb® was used to reduce the myoglobin levels.	1	Case report	Within 8 hours of starting CytoSorb®, myoglobin levels had decreased from 18,390 - 10,020. Renal function recovered and no side effects of the therapy were observed.



### CytoSorbents Europe GmbH

Müggelseedamm 131  
12587 Berlin | Germany

T +49 30 65 49 91 45  
F +49 30 65 49 91 46  
support@cytosorbents.com

[Register for the literature newsletter](#)

[Visit our literature database for an overview of all references](#)



[www.cytosorb.com](http://www.cytosorb.com)

The clinical and preclinical data and results obtained with the CytoSorb® adsorber are not transferable to other products. CytoSorb® should only be administered by health care professionals, properly trained in administration of extracorporeal therapies. The statements here represent the personal opinions and views of the author(s) only and do not necessarily reflect accepted medical knowledge in general or indications covered by the intended use of CytoSorb®. CytoSorb® and CytoSorbents are trademarks of the CytoSorbents Corporation, USA. © Copyright 2022, CytoSorbents Europe GmbH. All rights reserved. B1300R01ENG2022